InventisBio Co. Ltd. A
InventisBio Co., Limited, a clinical stage biotech company, engages in the discovery and development of therapeutics for cancer and metabolic diseases in China. The company's drug candidates for the oncology therapeutic area include BPI-D0316, which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; Taragarestrant, which is in Phase III clinical trial for the t… Read more
InventisBio Co. Ltd. A (688382) - Total Liabilities
Latest total liabilities as of June 2025: CN¥94.87 Million CNY
Based on the latest financial reports, InventisBio Co. Ltd. A (688382) has total liabilities worth CN¥94.87 Million CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
InventisBio Co. Ltd. A - Total Liabilities Trend (2020–2024)
This chart illustrates how InventisBio Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
InventisBio Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of InventisBio Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Galapagos NV
PINK:GLPGF
|
USA | $1.25 Billion |
|
HeiLongJiang Kingland Technology Co Ltd
SHE:000711
|
China | CN¥603.48 Million |
|
Caida Securities Co Ltd
SHG:600906
|
China | CN¥41.86 Billion |
|
Terveystalo Oy
HE:TTALO
|
Finland | €854.50 Million |
|
Bell Food Group AG
LSE:0RFX
|
UK | £1.61 Billion |
|
Bitdeer Technologies Group Class A Ordinary Shares
NASDAQ:BTDR
|
USA | $1.86 Billion |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥1.55 Billion |
|
Gubre Fabrikalari TAS
IS:GUBRF
|
Turkey | TL27.72 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down InventisBio Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 23.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how InventisBio Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for InventisBio Co. Ltd. A (2020–2024)
The table below shows the annual total liabilities of InventisBio Co. Ltd. A from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥110.03 Million | -33.18% |
| 2023-12-31 | CN¥164.67 Million | +23.90% |
| 2022-12-31 | CN¥132.90 Million | +15.57% |
| 2021-12-31 | CN¥115.00 Million | +86.99% |
| 2020-12-31 | CN¥61.50 Million | -- |